Bioventus Surgical expands portfolio with Premier: 3 takeaways

Effective on June 1, 2017, Bioventus’ full surgical orthobiologics portfolio was made available through premier.

Advertisement

Here are three takeaways:

 

1. Bioventus Surgical has numerous offerings for bone healing and spine fusion including allograft bone, synthetic bone graft substitutes and cell and marrow extraction needles.

 

2. There are eight new products in the expanded portfolio.

 

3. Senior Vice President Henry Tung, MD, said, “The Bioventus Surgical portfolio is designed to meet the needs of surgeons and their patients across a broad range of clinical situations, procedures and costs.”

 

More articles on devices and implants:
Global cervical total disc replacement device market to reach $1.8B by 2021 – 5 observations
Stryker celebrates completion of 100K joint replacement with Mako System – 3 points
Bioventus’ LIPUS an alternative to established nonunion fracture surgery: 4 insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.